Key Details
Annual ROE
-117.90%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 08, 2023Recent annual earnings:
Mar 15, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Nov 06, 2023Analyst ratings
Recent major analysts updates
26 Sept '23 Baird
Neutral15 Feb '23 Chardan Capital
Neutral14 Feb '23 Oppenheimer
Perform14 Feb '23 Baird
Outperform08 Dec '22 Chardan Capital
Buy02 Nov '22 Baird
Outperform24 May '22 Goldman Sachs
Neutral23 Mar '22 B. Riley Securities
Buy22 Sept '21 Goldman Sachs
Neutral24 Mar '21 Oppenheimer
OutperformScreeners with FREQ included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Frequency Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
NIKKI's Efficacy in Overcoming Lyme Disease to be Presented at 2024 Leap into Health Conference
FREQ
accesswire.com13 December 2024
VANCOUVER, BC / ACCESSWIRE / December 13, 2024 / Frequency Exchange Corp. ("Frequency Exchange" or the "Company") (TSXV:FREQ)(OTC PINK:FRECF), a company focused on the global commercialization of its proprietary "NIKKI" Wearable Wellness Technology, is pleased to announce Founder & CEO Stephen Davis will be presenting at the 2024 Quantum Leap Into Health Conference alongside Dr. Keith Pyne, DC, about NIKKI's efficacy in overcoming Lyme Disease. Dr Pyne's Story: Overcoming Lyme Disease with NIKKI Wellness Technology Dr. Keith Pyne, DC is a renowned medical advisor to professional sports organizations including the MLB, NBA, NHL and NFL, as well as Olympic and collegiate athletic teams.
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
FREQ
Zacks Investment Research17 July 2023
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Why Is Frequency Therapeutics (FREQ) Stock Up 44% Today?
FREQ
InvestorPlace14 July 2023
Frequency Therapeutics (NASDAQ: FREQ ) stock is rocketing higher on Friday following news that it will combine with Korro Bio . This merger plan is designed to bring Korro Bio public and will focus on the development of its RNA editing programs.
FAQ
- What is the primary business of Frequency Therapeutics?
- What is the ticker symbol for Frequency Therapeutics?
- Does Frequency Therapeutics pay dividends?
- What sector is Frequency Therapeutics in?
- What industry is Frequency Therapeutics in?
- What country is Frequency Therapeutics based in?
- When did Frequency Therapeutics go public?
- Is Frequency Therapeutics in the S&P 500?
- Is Frequency Therapeutics in the NASDAQ 100?
- Is Frequency Therapeutics in the Dow Jones?
- When was Frequency Therapeutics's last earnings report?
- When does Frequency Therapeutics report earnings?
- Should I buy Frequency Therapeutics stock now?
What is the primary business of Frequency Therapeutics?
As of November 3, 2023, Frequency Therapeutics, Inc. was acquired by Korro Bio, Inc., in a reverse merger transaction. Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
What is the ticker symbol for Frequency Therapeutics?
The ticker symbol for Frequency Therapeutics is NASDAQ:FREQ
Does Frequency Therapeutics pay dividends?
No, Frequency Therapeutics does not pay dividends
What sector is Frequency Therapeutics in?
Frequency Therapeutics is in the Healthcare sector
What industry is Frequency Therapeutics in?
Frequency Therapeutics is in the Biotechnology industry
What country is Frequency Therapeutics based in?
Frequency Therapeutics is headquartered in United States
When did Frequency Therapeutics go public?
Frequency Therapeutics's initial public offering (IPO) was on 03 October 2019
Is Frequency Therapeutics in the S&P 500?
No, Frequency Therapeutics is not included in the S&P 500 index
Is Frequency Therapeutics in the NASDAQ 100?
No, Frequency Therapeutics is not included in the NASDAQ 100 index
Is Frequency Therapeutics in the Dow Jones?
No, Frequency Therapeutics is not included in the Dow Jones index
When was Frequency Therapeutics's last earnings report?
Frequency Therapeutics's most recent earnings report was on 8 November 2023
When does Frequency Therapeutics report earnings?
The date for Frequency Therapeutics's next earnings report has not been announced yet
Should I buy Frequency Therapeutics stock now?
As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions